Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17418840 | 0.82 | USP7 (0.41) | KDM1ANPC1RAB9AMAPTHTT | |
| SCHEMBL17418966 | 0.80 | CTSA (0.41) | KDM1ANPC1RAB9APIM1CYP1A2 | |
| SCHEMBL17418748 | 0.75 | CTSA (0.41) | NPC1RAB9APIM1CYP1A2CYP3A4 | |
| SCHEMBL17418604 | 0.74 | FFAR1 (0.41) | NPC1RAB9A | |
| SCHEMBL29419518 | 0.72 | KDM1A (0.45) | KDM1ANPC1RAB9AMAPTKDM4E | |
| SCHEMBL28691083 | 0.72 | KDM1A (0.45) | KDM1ANPC1RAB9AMAPTKDM4E | |
| SCHEMBL30989187 | 0.71 | CYP3A4 (0.40) | KDM1ANPC1RAB9AMAPTKDM4E | |
| SCHEMBL2415584 | 0.70 | SCN2A (0.51) | KDM1ANPC1MAPTKDM4EHTT | |
| SCHEMBL2403768 | 0.70 | KDM1A (0.53) | KDM1ANPC1RAB9APIM1CYP1A2 | |
| SCHEMBL17419149 | 0.70 | NPC1 (0.41) | KDM1ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| WO-2016007714-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007714-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | KDM1A 3671/4885NPC1 1669/4885RAB9A 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.